Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer

doi:10.5306/wjco.v13.i8.712

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2785)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

124

WORD

HTML

1275

Figures (1-1)

219

Tables (1-4)

232

Sum=1891

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

250

Download

644

Sum=894

Aug 24, 2022 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Clin Oncol. Aug 24, 2022; 13(8): 712-724
Published online Aug 24, 2022. doi: 10.5306/wjco.v13.i8.712

Open in New Tab Full Size Figure Download Figure

Figure 1 Survival outcomes stratified by cytochrome P450 2D6 phenotype and by hormonal agent used. A: Kaplan-Meier curves showing 5-year recurrence-free survival stratified by cytochrome P450 2D6 phenotype (n = 70); B: Kaplan-Meier curves showing 5-year overall survival stratified by cytochrome P450 2D6 phenotype (n = 70); C: Kaplan-Meier curves showing 5-year recurrence-free survival stratified by hormonal agent received (n = 70); D: Kaplan-Meier curves showing 5-year overall survival stratified by hormonal agent received (n = 70). IM: Intermediate metabolizers; EM/UM: Extensive metabolizers/ultra metabolizers; AI: Aromatase inhibitors; HR: Hazard ratio; CI: Confidence interval.

Citation: Tan EY, Bharwani L, Chia YH, Soong RCT, Lee SSY, Chen JJC, Chan PMY. Impact of cytochrome P450 2D6 polymorphisms on decision-making and clinical outcomes in adjuvant hormonal therapy for breast cancer. World J Clin Oncol 2022; 13(8): 712-724
URL: https://www.wjgnet.com/2218-4333/full/v13/i8/712.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i8.712